Researchers Developed New Lung Cancer Imaging Metric
A deep learning model successfully identified tumor vascular abnormalities to predict patient survival outcomes.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you believe noninvasive imaging should be prioritized to help guide cancer immunotherapy treatment?
Researchers have developed a deep learning-based vascular risk score to quantify tumor vascular abnormalities using CT scans. The metric effectively identifies prognostic outcomes for patients with non-small cell lung cancer (NSCLC).
Why it matters
Morphological abnormalities in tumor vasculature serve as a key mechanism of resistance to immune checkpoint inhibitors. This new imaging tool provides a non-invasive way to better predict patient responses to treatment.
The vascular risk score was validated in a cohort of 321 NSCLC patients, demonstrating that lower scores correlate with longer progression-free and overall survival. Research remains ongoing regarding how this score integrates with established biomarkers.
The details
The model uses deep learning to learn representations of vascular morphology and Gaussian mixture modeling to quantify how tumor vasculature deviates from normal patterns. Combining this score with PD-L1 expression levels provided modest additional discrimination in patient outcomes.
Timeline
The findings were published on September 21, 2026.
The Big Picture
This study follows the trend of the development of AI-based predictive biomarkers in oncology by applying deep learning to standard imaging. It marks a shift toward using complex morphological data from routine scans to refine treatment planning.
This development may eventually provide patients with more accurate prognostic information based on standard CT scans. It potentially improves how oncologists choose therapies by accounting for specific vascular resistance mechanisms.
The takeaway
Advanced imaging analysis is proving to be a powerful tool in identifying how tumors resist conventional therapies. Patients should discuss new diagnostic testing options with their oncologists to determine if emerging imaging metrics apply to their specific care plan.
Further reading
For more information on current diagnostic developments, visit the Cancer section.
More information
View the complete peer-reviewed research article for detailed methodology.
Live Poll
Do you believe noninvasive imaging should be prioritized to help guide cancer immunotherapy treatment?
